Actym Therapeutics Appoints Mary J. Janatpour as Chief Scientific Officer and Shouryadeep Srivastava as Senior Vice President of Clinical Development
Position
Vice President
Company
Actym Therapeutics
BerkeleyBiotechnologyHealth CareMedicalTherapeuticsDescription
Actym Therapeutics announced the appointments of Mary J. Janatpour, PhD, as Chief Scientific Officer and Shouryadeep "Deep" Srivastava, MD, PhD, as Senior Vice President of Clinical Development, both bringing extensive therapeutic product discovery and development expertise. These appointments equip Actym with the leadership necessary to drive its product development and achieve its business objectives.
Quick answer
Actym Therapeutics Appoints Mary J. Janatpour as Chief Scientific Officer and Shouryadeep Srivastava as Senior Vice President of Clinical Development (June 25, 2024). Actym Therapeutics is based in Berkeley, California, United States.
- Who is the new Vice President at Actym Therapeutics?
- Actym Therapeutics named Shouryadeep Srivastava Vice President, announced June 25, 2024.
- What did Actym Therapeutics announce on June 25, 2024?
- Actym Therapeutics announced the appointments of Mary J. Janatpour, PhD, as Chief Scientific Officer and Shouryadeep "Deep" Srivastava, MD, PhD, as Senior Vice President of Clinical Development, both bringing extensive therapeutic product discovery and development expertise. These appointments equip Actym with the leadership necessary to drive its product development and achieve its business objectives.
- What does Actym Therapeutics do?
- Actym Therapeutics is a cutting-edge biotech focused on the discovery and development of novel immuno-oncology therapies.
- Where is Actym Therapeutics based?
- Actym Therapeutics is based in Berkeley, California, United States.
- Which similar companies made leadership changes around the same time?
- Immunome Inc. (June 27, 2024), Medical Technology Enterprise Consortium (MTEC) (June 14, 2024), NYU Langone Health (July 25, 2024) and Pulse Biosciences, Inc. (May 14, 2024) also announced leadership changes within 45 days of Actym Therapeutics.
Source: Fundz verified event record.
Other recent leadership changes in Medical and Therapeutics
Executive moves at companies in the same sectors within 45 days, from Fundz verified event records.
- Immunome Appoints Phil Tsai, PhD, as Chief Technical Officer (June 27, 2024)
- MTEC Appoints Dr. Shawn Green as President and RET. CDR. Christopher Steele as Chief of Strategy and Business Development (June 14, 2024)
- NYU Langone Health's Perlmutter Cancer Center Names Jonathan M. Gerber, MD, as Chief Clinical Officer (July 25, 2024)
- Pulse Biosciences Appoints Burke T. Barrett as President and CEO, and Kevin Danahy as Chief Commercial Officer (May 14, 2024)
- Nanoscope Therapeutics Inc. Appoints Khandan Baradaran as Senior Vice President of Regulatory and Quality (May 14, 2024)
- MBX Biosciences Appoints Salomon (Sam) Azoulay, M.D, as Chief Medical Officer (June 25, 2024)
Who to call at Actym Therapeutics, and when
A new leader at Actym Therapeutics brings new priorities and often new vendors. The first weeks are when they listen.
- An alert the day Actym Therapeutics raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Actym Therapeutics, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Actym Therapeutics. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Actym Therapeutics changes its leadership, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Actym Therapeutics changed its leadership. Fundz had it the day it was filed, with the decision-maker at the company attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.